Lineage Cell Therapeutics (LCTX) Operating Expenses (2010 - 2026)

Lineage Cell Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 16.37% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $52.5 million, a 69.97% increase from a year earlier, with the FY2025 full-year figure at $51.2 million, up 65.2% from the prior year.
• Operating Expenses declined to $9.3 million in Q1 2026 per LCTX's latest filing, from $13.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $22.5 million in Q2 2025 and bottomed at $7.3 million in Q2 2024.
• The 5-year median for Operating Expenses is $8.2 million (2023), against an average of $9.5 million.
• Across the five-year window, Operating Expenses plunged 71.06% in 2022 and jumped 209.9% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $8.5 million in 2022, then declined by 3.05% to $8.2 million in 2023, then decreased by 2.64% to $8.0 million in 2024, then jumped by 64.9% to $13.2 million in 2025, then fell by 29.17% to $9.3 million in 2026.
• Per Business Quant, the three latest LCTX Operating Expenses figures stand at $9.3 million (Q1 2026), $13.2 million (Q4 2025), and $7.5 million (Q3 2025).